Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
Jul 25, 2017 12:30 pm UTC| Business
NORCROSS, Ga., July 25, 2017 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a...
Aqua Metals Announces Preliminary Q2 2017 Revenues
Jul 25, 2017 12:30 pm UTC| Business
ALAMEDA, Calif., July 25, 2017 -- Aqua Metals, Inc. (NASDAQ:AQMS) (“Aqua Metals” or the “Company”), which is commercializing a non-polluting electrochemical lead recycling technology called AquaRefining™, has provided...
Points International to Report Second Quarter 2017 Results on Wednesday, August 9, 2017
Jul 25, 2017 12:30 pm UTC| Business
TORONTO, July 25, 2017 -- Points (TSX:PTS) (Nasdaq:PCOM), the global leader in powering loyalty commerce, today announced that it will report financial results for the second quarter ended June 30, 2017, on Wednesday,...
Coupa Named as a Leading Global AP Automation Provider in 2017 Report by PayStream Advisors
Jul 25, 2017 12:30 pm UTC| Business
EDITOR’S NOTE: PayStream Advisors will host a webinar on the state of global e-Invoicing on August 1. Anna Barnett, an author of the PayStream report, and Markus Hornburg, Coupa vice president of global product compliance,...
MariMed Names New CEO, CFO; Finalizes Transition To Focus Solely on Cannabis Industry
Jul 25, 2017 12:29 pm UTC| Business
NEWTON, Mass., July 25, 2017 -- The MariMed Inc., (OTCQB:MRMD) Board of Directors has appointed Mr. Robert Fireman as President and Chief Executive Officer (CEO) and Mr. Jon Levine as Treasurer and Chief Financial...
Cystic Fibrosis Therapeutics Market, 2022
Jul 25, 2017 12:27 pm UTC| Business
Dublin, July 25, 2017 -- The "Global Cystic Fibrosis Therapeutics Market Outlook 2022" report has been added to Research and Markets' offering. The market for cystic fibrosis...
Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
Jul 25, 2017 12:15 pm UTC| Business
GERMANTOWN, Md., July 25, 2017 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced top-line results from its exploratory Phase 2...